Figure 3 | Scientific Reports

Figure 3

From: The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy

Figure 3

The association of blood tumor mutation burden (bTMB) with clinical outcome of gastric cancer patients received nivolumab monotherapy. Disease control rate (DCR, a), and Kaplan–Meier estimates of progression-free survival (PFS, b), as well as overall survival (OS, c) of patients stratified by bTMB of 4 mut/Mb. Disease control rate (DCR, d), and Kaplan–Meier estimates of PFS (e), as well as OS (f), of patients stratified by bTMB of 6 mut/Mb.

Back to article page